The report "Anatomic Pathology Market by Product & Service (Instruments (Cell Processor, Microtome), Consumable, Histopathology, Cytopathology, Application (Disease Diagnosis (Cancer (Breast, Lung), End User (Hospital Laboratories), Region - Global Forecasts to 2026", is projected to reach USD 49.1 billion by 2026 from USD 35.1 billion in 2021, at a CAGR of 7.0%. The growth of the anatomic pathology market is majorly driven by the high incidence of cancer and other target diseases, recommendations for cancer screening, availability of reimbursement, and the growing focus on personalized medicine. In addition, emerging economies such as China, India, and Brazil are expected to offer significant growth opportunities for players operating in the anatomic pathology market during the forecast period.
Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=137323145
The global anatomic pathology market is expected to grow significantly over the coming years, due to a variety of factors, including the increasing prevalence of cancer, growing awareness of the importance of early diagnosis and prevention of diseases, the introduction of new technology, and the increasing availability of sophisticated diagnostic tests. The market is also expected to benefit from the development of advanced diagnostic tools and technologies, such as digital pathology and artificial intelligence (AI).
However, the growth of the anatomic pathology market is also faced with several challenges. These include the high cost of diagnostic tests, the lack of skilled personnel, the complexity of the procedure, and the slow adoption of new technologies. Additionally, the lack of reimbursement policies and the lack of regulatory guidance can pose a challenge to the growth of the market.
To overcome these challenges, the market players need to focus on developing new technologies and services, such as digital pathology and AI-based diagnostic tools. Additionally, they also need to focus on creating awareness among healthcare providers and patients about the importance of timely diagnosis and prevention of diseases.
Request For Customization on Anatomic Pathology Market Report @ https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=137323145
Key Market Players
The global anatomic pathology market for instruments and consumables is consolidated. The top five companies in this market are F. Hoffmann-La Roche AG (Switzerland), Danaher Corporation (US), PHC Holdings Corporation (Japan), Beckton, Dickson and Company (US), and Abcam plc. (UK).
F. Hoffmann-La Roche AG (Switzerland) was the leading player in the anatomic pathology market. The company has a wide range of products in the consumables segment. Strong business operations across all key regions, coupled with a strong brand image, make the firm a leading player in this market. F. Hoffman-La Roche has adopted organic business strategies such as product launches in order to maintain its leading position in the anatomic pathology market.
Danaher Corporation (US) was the second-leading player in the anatomic pathology market. The company has a broad product portfolio in the instruments segment. Moreover, Danaher also has a strong geographic presence with its direct distribution channels across the globe. The impressive product portfolio of the firm is complemented by its client support services. Over the years, Danaher has maintained its leading position in the market through continuous innovation and the launch of advanced products.
North America dominates the anatomic pathology market
The global anatomic pathology market is segmented into North America, Europe, the Asia Pacific, and the Rest of the World (RoW). North America accounted for the largest share of the anatomic pathology market. Factors such as the rising prevalence of chronic diseases, increasing healthcare expenditure, the high-quality infrastructure for hospitals and clinical laboratories, and the presence of major market players in the region are driving the growth of the anatomic pathology market in North America.
Recent Developments:
· Hologic received premarket approval (PMA) from the FDA for its ThinPrep GenesisTM processor for cytology processing and specimen transfer for downstream applications.
· PHC Holding Corporation completed the acquisition of Thermo Fisher Scientific’s Anatomical Pathology business to strengthen its position in the diagnostics segment.
Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=137323145
About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
